NCT07314229Recruiting
Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified. The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 24 Nov 2025
- Start date
- 17 Dec 2025
- Primary completion date
- 2 Feb 2027
- Lead sponsor
- University Hospital, Lille
- Diseases
- Cystic fibrosis
- NCT number
- NCT07314229
What you commit to
- Study type: Interventional
- Planned participants: 130
- From 17 Dec 2025 to the primary completion date, 2 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Exacerbation of the condition in the 4 weeks preceding the V1 visit (27).
Other
- Medical contraindication or inability to perform a stress test according to ERS recommendations
- Absolute contraindications
- Relative contraindications:
- Pregnant or breastfeeding women
- Administrative reasons
- Persons deprived of their liberty
- Minors or protected adults
- Persons who have refused or are unable to give informed consent
- Persons in emergency situations
Who the study is looking for
- Male or female
- Adult aged 18 or over
- Suffering from cystic fibrosis
- Treated at the CRCM in Lille and Créteil
- Treated by ETI
- Be covered by social security
- Be able to understand the requirements of the study, provide written informed consent, and comply with the study's data collection procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital, Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.